These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 25592855)

  • 1. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.
    Ravani P; Rossi R; Bonanni A; Quinn RR; Sica F; Bodria M; Pasini A; Montini G; Edefonti A; Belingheri M; De Giovanni D; Barbano G; Degl'Innocenti L; Scolari F; Murer L; Reiser J; Fornoni A; Ghiggeri GM
    J Am Soc Nephrol; 2015 Sep; 26(9):2259-66. PubMed ID: 25592855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study.
    Ravani P; Lugani F; Pisani I; Bodria M; Piaggio G; Bartolomeo D; Prunotto M; Ghiggeri GM
    Pediatr Nephrol; 2020 Aug; 35(8):1437-1444. PubMed ID: 32232637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.
    Ravani P; Magnasco A; Edefonti A; Murer L; Rossi R; Ghio L; Benetti E; Scozzola F; Pasini A; Dallera N; Sica F; Belingheri M; Scolari F; Ghiggeri GM
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1308-15. PubMed ID: 21566104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multicenter survey of diagnostic and therapeutic status in Chinese childhood patients with steroid-sensitive, relaping/steroid-dependent nephrotic syndrome].
    Working Group For National Survey On Status Of Diagnosis And Treatment Of Childhood Renal Diseases
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):194-200. PubMed ID: 24824389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P; Bonanni A; Ghiggeri GM
    BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotic syndrome: Efficacy of rituximab in challenging nephrotic syndrome.
    Lemley KV; Mak RH
    Nat Rev Nephrol; 2015 May; 11(5):257-8. PubMed ID: 25752834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
    Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
    BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
    BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.
    Sato M; Kamei K; Ogura M; Ishikura K; Ito S
    Clin Exp Nephrol; 2018 Feb; 22(1):110-116. PubMed ID: 28434126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
    Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
    Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
    DaSilva I; Huerta A; Quintana L; Redondo B; Iglesias E; Draibe J; Praga M; Ballarín J; Díaz-Encarnación M;
    BioDrugs; 2017 Jun; 31(3):239-249. PubMed ID: 28534103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
    Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
    Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
    Ahn YH; Kim SH; Han KH; Choi HJ; Cho H; Lee JW; Shin JI; Cho MH; Lee JH; Park YS; Ha IS; Cheong HI; Kim SY; Lee SJ; Kang HG
    Medicine (Baltimore); 2018 Nov; 97(46):e13157. PubMed ID: 30431588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review.
    Jellouli M; Charfi R; Maalej B; Mahfoud A; Trabelsi S; Gargah T
    J Pediatr; 2018 Jun; 197():191-197.e1. PubMed ID: 29680473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.